BioPharmSignal logoBioPharmSignal

Biotech News

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

Adagene (ADAG)AdageneConference / presentation

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA.

Related news

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

ADAGAdagene2026-10-14 12:00 EST

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

View all latest news

Adagene

Adagene is a biotechnology company focused on next-generation antibody engineering and cancer immunotherapy. Its story is built around precision antibody design and the effort to create differentiated oncology medicines.

Recent company news

ADAGAdagene2026-10-28 11:00 EST

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

ADAGAdagene2026-10-27 11:00 EST

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

ADAGAdagene2026-10-14 12:00 EST

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

ADAGAdagene2026-09-22 12:00 EST

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

ADAGAdagene2026-09-10 12:00 EST

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Stock data

Close
2.02 USD
Market cap
223.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States